Steve Middleton

Title: Innovations of Steve Middleton

Introduction

Steve Middleton is an accomplished inventor based in Flemington, NJ (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of kinase inhibitors. With a total of 2 patents, his work has the potential to impact various medical treatments.

Latest Patents

Middleton's latest patents include "Substituted triazine kinase inhibitors," which provides substituted 1,3,5-triazine compounds as kinase inhibitors. This invention offers a method for treating or ameliorating kinase-mediated disorders. Another notable patent is "Pyrazine derivatives as modulators of tyrosine kinases." This invention presents pyrazine derivatives that inhibit tyrosine kinase activity, with certain derivatives being selective inhibitors of vascular endothelial growth factor (VEGF) receptor tyrosine kinase. The patent also includes pharmaceutical formulations containing these pyrazine derivatives, which can be used as anti-tumor agents and to treat conditions such as solid-tumor cancers, angiogenesis, diabetic retinopathy, rheumatoid arthritis, endometriosis, and psoriasis.

Career Highlights

Throughout his career, Middleton has worked with prominent companies in the pharmaceutical industry, including Ortho-McNeil Pharmaceutical Corporation and Janssen Pharmaceutica NV. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Some of his notable coworkers include Gee-Hong Kuo and Alan DeAngelis. Their collaborative efforts have likely played a role in advancing Middleton's research and inventions.

Conclusion

Steve Middleton's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving medical treatments. His work continues to pave the way for advancements in the treatment of various diseases.